Anti-ARIH1 抗体

ターゲットの情報

E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed : 15236971, PubMed : 21532592, PubMed : 23707686, PubMed : 24076655, PubMed : 27565346). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates : associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed : 27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed : 27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin-RING ubiquitin ligase complexes (PubMed : 24076655, PubMed : 27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed : 25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed : 25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed : 14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed : 17289916). In vitro, controls the degradation of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex member SUN2 and may therefore have a role in the formation and localization of the LINC complex, and as a consequence, nuclear subcellular localization and nuclear morphology (PubMed : 29689197).